Vericel (VCEL) CMO sells 3,472 shares after option exercise under 10b5-1 plan
Vericel's Chief Medical Officer, Jonathan Mark Hopper, exercised stock options for 3,472 shares at $10.95 and subsequently sold those shares at $35.00 on April 2, 2026, under a pre-planned 10b5-1 trading plan. After these transactions, Hopper directly holds 75,556 common shares and 9,132 exercisable stock options. The original option grant for 135,000 shares had a vesting schedule and an expiration date of August 20, 2028.
Aberdeen Group plc Has $21.03 Million Stock Position in Vericel Corporation $VCEL
Aberdeen Group plc increased its stake in Vericel Corporation (NASDAQ:VCEL) by 7.6% in the fourth quarter, now holding 583,884 shares valued at $21.03 million. Other institutional investors also adjusted their positions in the biotechnology company. Vericel reported strong quarterly earnings with $0.45 EPS, meeting estimates, and revenue up 23.3% year-over-year, while analysts maintain a "Moderate Buy" rating with an average price target of $56.00.
U.S. burn emergency stockpile gets NexoBrid in $197M BARDA pact
Vericel (NASDAQ:VCEL) has secured a ten-year contract with BARDA, valued at up to $197 million, for the procurement and advanced development of its severe burn treatment, NexoBrid. This agreement includes an initial $35 million base period, with approximately $10 million allocated for procurement and Vendor Managed Inventory (VMI) over the next 12 months, aimed at expanding the U.S. Strategic National Stockpile. The contract also covers the design of a U.S. manufacturing facility and the development of a room-temperature stable formulation and a blast trauma indication for NexoBrid.
[144] Vericel Corp SEC Filing
This article reports on a Form 144 SEC filing by Vericel Corp (VCEL) on April 2, 2026. The filing indicates a proposed sale of 3,472 shares of common stock by an individual, acquired through an option grant on August 20, 2018. The aggregate market value of the securities to be sold is $121,520.00, and the sale is expected to occur on April 2, 2026, via Fidelity Brokerage Services LLC on NASDAQ.
VCEL SEC Filings - Vericel 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Vericel's (VCEL) SEC filings, including annual 10-K reports, quarterly 10-Q reports, 8-K material event reports, and insider trading forms. It details the company's financial information, business operations in advanced therapies for sports medicine and burn care, and risk factors. The platform also offers AI-powered summaries, impact scoring, and sentiment analysis for each filing to enhance investor understanding.
VCEL SEC Filings - Vericel 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides a comprehensive resource for Vericel (VCEL) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It details recent insider transactions and preliminary 2025 financial results, with AI-powered summaries and real-time updates to help investors understand the company's regulatory disclosures. The filings offer insights into Vericel's business in advanced therapies and associated financial performance and risks.
Soleus discloses 2.55M Vericel shares (NASDAQ: VCEL)
Soleus Capital Master Fund, L.P. and its affiliated entities have reported a 5.0% passive stake in Vericel Corp, holding 2,549,079 shares of common stock. This disclosure was made via a Schedule 13G filing with the SEC, based on Vericel's outstanding shares as of February 19, 2026. The filing indicates shared voting and dispositive power among the affiliated entities, with Guy Levy signing the joint agreement.
VCEL SEC Filings - Vericel 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Vericel's (VCEL) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside Form 4 insider trading reports. It highlights recent insider transactions involving RSU vesting and grants for top executives in February 2026, as well as the company's strong 2025 financial results and 2026 revenue projections. The platform uses AI to summarize documents and analyze sentiment for investors.
[Form 4] Vericel Corp Insider Trading Activity
Vericel Corp director Alan L. Rubino exercised options to acquire 15,000 shares of common stock at $2.76 per share and chose to retain all of them. These options were granted in May 2016 and would have expired in May 2026. Following this transaction, Rubino directly owns 60,994 shares, and the exercised option grant is fully utilized.
Vericel corp director Hagen sells $486k in shares By Investing.com
Heidi Hagen, a director at Vericel Corp (NASDAQ:VCEL), sold 15,000 shares of common stock for $486,149 on March 23, 2026, executed under a pre-arranged trading plan. This sale occurred near the stock's 52-week low. Despite the stock sale, Vericel is considered undervalued by InvestingPro, boasts a Piotroski Score of 9, and recently reported strong Q4 2025 financial results, exceeding revenue and EPS forecasts.
Vanguard disaggregates holdings; files 13G/A for Vericel (VCEL)
The Vanguard Group filed an amended Schedule 13G/A for Vericel Corp (VCEL), reporting zero beneficial ownership of its common stock. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their ownership separately, as per SEC Release No. 34-39538. Vanguard's filing states it no longer beneficially owns these securities, with reporting responsibilities shifting to the individual subsidiaries.
Vericel corp director Hagen sells $486k in shares By Investing.com
Vericel Corp director Heidi Hagen sold 15,000 shares of common stock for $486,149 and exercised options to acquire 15,000 shares. The company, with a $1.57 billion market cap, is considered undervalued by InvestingPro, boasting a perfect Piotroski Score of 9. This news follows strong Q4 2025 financial results, FDA approval for its new MACI production facility, and raised price targets from analysts.
Vericel corp director Hagen sells $486k in shares
Vericel Corp director Heidi Hagen sold 15,000 shares of common stock for $486,149 on March 23, 2026, as the stock traded near its 52-week low. The sale was made under a pre-arranged trading plan, and Hagen also exercised options for 15,000 shares on the same day. Despite the insider sale, Vericel appears financially healthy and recently reported strong Q4 2025 results, leading to raised price targets from analysts.
Vericel (VCEL) director sells 15,000 shares after option exercise
Vericel director Heidi Hagen exercised stock options to acquire 15,000 shares of common stock at $2.76 per share and subsequently sold the same 15,000 shares at $32.41 per share on March 23, 2026. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Hagen directly holds 31,850 shares of Vericel common stock.
Vericel Corporation $VCEL Position Increased by Congress Asset Management Co.
Congress Asset Management Co. increased its stake in Vericel Corporation ($VCEL) by 11.4% during the fourth quarter, now owning 3.29% of the company's shares. Vericel reported strong quarterly results with EPS of $0.45 and revenue up 23.3% year-over-year, meeting analyst estimates. Analyst ratings are mixed-to-positive, with an average "Moderate Buy" rating and a price target of $56.
[144] Vericel Corp SEC Filing
This SEC filing (Form 144) for Vericel Corp (VCEL) details a proposed sale of 15,000 shares of common stock with an aggregate market value of $486,162.53, acquired through an option granted on May 4, 2016. The transaction is set for March 23, 2026, and will be handled by Fidelity Brokerage Services LLC on NASDAQ. The filing indicates a "Neutral" impact and sentiment.
Vericel Corp. Experiences Revision in Its Stock Evaluation Amid Market Challenges
Vericel Corp., a small-cap pharmaceutical and biotechnology company, has seen a revision in its stock evaluation. Despite high financial metrics like a P/E ratio of 256 and a significant 29.38% stock decline over the past year, the company has demonstrated resilience with a 21.61% return over three years. This performance is noted against a backdrop of competitive market challenges and a high valuation compared to its peers.
Dilated Cardiomyopathy Market: Rapid Growth & Investment Outlook to 2034 – DelveInsight | Bristol Myers Squibb, Berlin Cures, Cumberland Pharma, Vericel Corp, Corimmun GmbH, Pfizer, Constant Therapeut
The Dilated Cardiomyopathy (DCM) market is projected for significant growth, driven by increasing prevalence and awareness. In 2023, the market was valued at approximately $463 million, with the US holding the largest share. Key players like Bristol Myers Squibb, Berlin Cures, and Pfizer are developing new therapies, including AFTX-201 which recently received FDA Fast Track designation for BAG3-associated DCM.
Leerink reiterates Outperform on Vericel stock, $46 target
Leerink Partners has reiterated its Outperform rating on Vericel Corporation (NASDAQ:VCEL) with a $46 price target, citing strong momentum in MACI KPIs and expected continued growth, particularly with MACI Arthro. The company reported impressive Q4 2025 results, exceeding revenue and EPS forecasts, and analysts predict 17% growth for fiscal 2026, supported by a 74% gross profit margin. FDA approval for MACI commercial production at its new facility also positions Vericel for continued success.
Vericel Corporation (VCEL) Secures FDA Approval for Commercial Manufacturing of MACI
Vericel Corporation (VCEL) announced it received FDA approval for the commercial manufacturing of MACI, its restorative cartilage repair product, at its Burlington, Massachusetts facility. This approval will allow Vericel to boost MACI production starting in Q2 2026 to meet growing demand and enhance supply chain resilience. The company aims for international commercialization of MACI, emphasizing its scientific and operational advancements in cell therapy.
Vericel Corporation (VCEL) Secures FDA Approval for Commercial Manufacturing of MACI
Vericel Corporation (NASDAQ: VCEL) announced receiving FDA approval for the commercial manufacturing of MACI, its autologous cultured chondrocytes product, at its Burlington, Massachusetts facility. This approval allows Vericel to significantly increase production starting in Q2 2026 to meet growing demand for the knee repair product and supports potential international commercialization. The company sees this as a major milestone, enhancing supply chain resilience and showcasing its advancements in cell therapies.
Vericel (VCEL) Is Down 9.8% After FDA Clears New MACI Plant – Has The Bull Case Changed?
Vericel Corporation received FDA approval for commercial manufacturing of its MACI cartilage repair therapy at a new Burlington facility, with production starting in Q2 2026. This approval, while positive for capacity and potential international expansion, did not prevent a 9.8% stock drop, as key risks like payer pressure and execution challenges remain. The company's investment narrative relies on sustained therapy adoption and profitable scaling, with forecasts projecting significant revenue and earnings by 2028 and an upside to its current price.
Vericel (VCEL) COO sells 10,305 shares in automatic Rule 10b5-1 trade
Vericel Corp's COO, Michael Halpin, sold 10,305 shares of common stock at $35.30 per share on March 2, 2026. This transaction was an automatic sale conducted under a Rule 10b5-1 trading plan established on December 2, 2025. Following the sale, Halpin directly owns 16,080 shares of Vericel.
Insider Sell: Michael Halpin Sells 10,305 Shares of Vericel Corp (VCEL)
Michael Halpin, the Chief Operating Officer of Vericel Corp, sold 10,305 shares of the company on March 2, 2026. This transaction reduces his total holdings to 16,080 shares. Over the past year, Vericel Corp has seen 16 insider sales and no insider purchases, with Halpin alone selling 30,305 shares. The stock is currently trading at $35.3, with a market cap of $1.768 billion, and is deemed significantly undervalued according to its GF Value of $50.86.
FDA Greenlights Vericel (VCEL) Facility for MACI Production
Vericel Corporation received FDA approval to begin commercial manufacturing of MACI at its Burlington, Massachusetts facility in Q2 2026, boosting its capacity and international expansion potential. The company, focused on cell therapy for sports medicine and burn care, exhibits strong financial metrics like high gross margins and liquidity, though insider selling and a low ROIC against WACC are noted. Analyst sentiment is positive, with valuation metrics suggesting potential undervaluation despite sector-specific risks.
FDA approves new Vericel cell therapy plant to expand cartilage repair
Vericel (NASDAQ: VCEL) has received FDA approval for its new state-of-the-art cell therapy manufacturing facility in Burlington, Massachusetts, enabling commercial production of MACI for cartilage repair to begin in Q2 2026. This approval significantly increases manufacturing capacity to support long-term growth and paves the way for potential international commercialization of MACI. The company anticipates that this milestone will strengthen its supply chain and meet increasing demand for its restorative cartilage repair product.
Vericel (VCEL) CLO trades 21,421 shares under Rule 10b5-1 plan
Vericel Corp's Chief Legal Officer, Sean C. Flynn, exercised options for 15,000 shares and sold a total of 21,421 common shares of VCEL on March 2, 2026. The sales, executed at prices around $34.75 and $35.36, were made under an automatic Rule 10b5-1 trading plan adopted on December 2, 2025. Following these transactions, Flynn directly held 1,262 common shares and 85,000 option-based rights.
Affiliate sale notice for Vericel (NASDAQ: VCEL) — 15,000 shares listed
Vericel Corporation filed a Form 144 indicating a proposed affiliate sale of 15,000 common shares through Fidelity Brokerage Services LLC, linked to an option exercise from November 2019. The filing also noted recent restricted stock vesting events between February 17 and February 22, 2026. This Form 144 serves as a notice of intent to sell, with actual sales to be reported in future Forms 4 or 5.
VCEL (NASDAQ: VCEL) Form 144 lists vested share sale entries
Vericel (VCEL) has filed a Form 144 detailing planned sales of common stock held at Fidelity Brokerage Services LLC. The filing specifically lists multiple restricted stock vesting entries occurring between February 17, 2026, and February 22, 2026, involving a total of 10,205 shares. Fidelity Brokerage Services LLC is identified as the broker, with Nasdaq as the market for these transactions.
Vericel (VCEL) CMO logs RSU vesting, phantom stock and tax share withholdings
Vericel's Chief Medical Officer, Jonathan Mark Hopper, reported RSU vesting activity, which included conversions to common stock and deferrals into phantom stock under the company's Deferred Compensation Plan. The company withheld 1,335 and 636 shares of common stock to cover tax obligations, valued at $38.09 and $38.25 per share respectively. Following these transactions, Hopper directly owned 75,556 shares of Vericel common stock.
Vericel (NASDAQ:VCEL) Given New $64.00 Price Target at HC Wainwright
HC Wainwright has increased its price target for Vericel (NASDAQ:VCEL) to $64.00 from $60.00, maintaining a "buy" rating and implying a 77% upside. Despite this, Vericel's shares traded down approximately 4.2% to $36.09, even after the company reported in-line quarterly earnings of $0.45 EPS and a 23.3% year-over-year revenue increase to $92.92 million. Several institutional investors, including William Blair and State Street, have significantly increased their positions in the biotechnology company.
Vericel Corporation (NASDAQ:VCEL) Q4 2025 Earnings Call Transcript
Vericel Corporation reported strong financial results for Q4 2025, with record revenue of $92.9 million and 23% growth. The company achieved significant margin expansion, with a gross margin of nearly 80% and adjusted EBITDA margin of 40%. Vericel also provided 2026 revenue guidance of $316 million to $326 million, anticipating continued strong growth for its MACI and Burn Care franchises, while also expecting potential outperformance from ongoing initiatives and the expanded sales force.
Vericel Corp (NASDAQ:VCEL) Presents a Compelling Growth and Breakout Case
Vericel Corp (NASDAQ:VCEL) is presented as a compelling investment opportunity, aligning strong fundamental growth with a potential technical breakout. The company exhibits robust past and projected EPS growth, high profitability margins, and a debt-free balance sheet, earning a good Health Rating. Technically, the stock is consolidating near a resistance level, indicating a possible breakout.
COO at Vericel (VCEL) gains stock through RSU vesting and tax withholding
Vericel Corp's Chief Operating Officer, Michael Halpin, acquired shares through RSU vesting on February 24, 2026, receiving 5,250 units in two separate transactions. To cover tax withholding obligations, 2,486 shares were withheld in two instances at fair market values of $38.09 and $38.25 per share respectively. Following these transactions, Halpin directly holds 26,385 shares of Vericel common stock, with additional RSU awards set to vest annually through February 2029.
RSU vesting boosts Vericel (VCEL) officer Siegal’s shareholding
Vericel Corporation's Principal Accounting Officer, Jonathan Siegal, increased his shareholding through the vesting of Restricted Stock Units (RSUs) on February 24, 2026. He acquired a total of 3,415 shares, with 1,365 shares withheld by the company to cover tax obligations. Following these transactions, Siegal directly owned 5,847 shares of Vericel common stock, with additional unvested RSUs set to vest in future years.
Vericel Corporation (VCEL) Matches Q4 Earnings Estimates
Vericel Corporation (VCEL) reported Q4 earnings of $0.45 per share, matching the Zacks Consensus Estimate and showing an increase from $0.38 per share a year ago. The company's revenues for the quarter were $92.92 million, surpassing estimates by 1.83%. Despite outperforming the market year-to-date, VCEL currently holds a Zacks Rank #3 (Hold).
Vericel Corp (NASDAQ:VCEL) Reports Q4 2025 Earnings In Line, Beats on Profitability
Vericel Corporation (NASDAQ:VCEL) announced Q4 and full-year 2025 financial results, with Q4 revenue meeting analyst expectations at $92.9 million and diluted EPS beating estimates at $0.45 per share. Total 2025 revenue grew 16% to $276.3 million, driven by strong MACI sales, while net income increased by 59%. The company provided 2026 revenue guidance between $316 million and $326 million, which is slightly below current analyst consensus.
Vericel Corp Ord earnings beat by $0.06, revenue topped estimates
Vericel Corp Ord (NASDAQ: VCEL) reported strong financial results for the fourth quarter, with EPS of $0.45, surpassing analyst estimates by $0.06, and revenue of $92.92 million, exceeding the consensus estimate of $90.71 million. Despite this beat, the company's stock price has seen a decline of 7.85% in the last 3 months and 25.25% in the last 12 months. InvestingPro rates Vericel Corp Ord's financial health as "great performance."
Vericel Corp SEC 10-K Report
Vericel Corporation has released its annual 10-K report detailing significant financial growth, strategic initiatives, and operational highlights. The report emphasizes expanding its product portfolio, enhancing manufacturing capabilities, and pursuing new market opportunities, driven by strong revenues from MACI, Epicel, and NexoBrid. The company reported total revenue of $276.3 million, a net income of $16.5 million, and is focused on R&D for new indications, international expansion, and leveraging a new manufacturing facility while addressing operational risks and market challenges.
Vericel Corporation Reports Fourth Quarter and Full-Year 2025 Financial Results
Vericel Corporation announced strong financial results for Q4 and full-year 2025, with significant revenue and net income growth driven by its MACI product line. The company reported a 23% increase in Q4 revenue to $92.9 million and a 16% full-year revenue growth to $276.3 million. Vericel also highlighted key business achievements including record MACI sales and advancements in clinical studies and manufacturing, projecting continued growth for 2026.
VCEL Technical Analysis & ETF Price Forecast
This article provides a technical analysis of Vericel Corp (VCEL), indicating a Neutral overall sentiment. While moving averages suggest a "Buy" signal, various momentum indicators like RSI, MACD, and Stochastic Oscillator point to a neutral condition. The analysis also highlights key support and resistance levels for VCEL's share price.
Vericel Corporation $VCEL Shares Acquired by CenterBook Partners LP
CenterBook Partners LP significantly increased its stake in Vericel Corporation (NASDAQ:VCEL) by 171.1% in the third quarter, now owning 184,986 shares valued at approximately $5.82 million. Other institutional investors have also adjusted their holdings. Analysts have a "Moderate Buy" consensus rating for VCEL, with a target price of $57.50, against its recent trading price near $36.82.
Vericel stock hits 52-week high at $35.84 despite yearly decline By Investing.com
Vericel Corporation's stock (VCEL) recently hit $35.84, a high despite a 38% decline over the past year. Analysts maintain a "strong buy" consensus with price targets up to $62, and InvestingPro indicates the stock is undervalued with "GREAT" financial health. The company projects approximately $276 million in total revenue for 2025, showing 23% growth in Q4, and BTIG reiterated a Neutral rating following better-than-anticipated Q3 results.
Vericel stock hits 52-week high at $35.84 despite yearly decline
Vericel stock recently reached a high of $35.84, a notable recovery despite a 38% decline over the past year. Analysts maintain a "strong buy" consensus with price targets up to $62, and InvestingPro data indicates the stock is undervalued with "GREAT" financial health. The company also announced preliminary unaudited 2025 revenues of $276 million, showing strong growth in Q4.
Thrivent Financial for Lutherans Trims Stock Holdings in Vericel Corporation $VCEL
Thrivent Financial for Lutherans significantly reduced its stake in Vericel Corporation (NASDAQ:VCEL) by 36.8% in the third quarter, selling 116,509 shares. Despite this, Vericel reported a stronger-than-expected quarter with $0.10 EPS, beating previous consensus estimates. The stock, currently trading in the mid-$30s, holds a "Moderate Buy" consensus rating from analysts.
Vericel Corp (NASDAQ:VCEL) Presents a Strong Growth and Breakout Setup
Vericel Corp (NASDAQ:VCEL) is highlighted as an attractive investment due to its robust fundamental growth, including significant EPS and sales increases, and strong profitability in the biotechnology sector. Technically, the stock shows a potential breakout setup with a sideways trading pattern near support and minimal overhead resistance. This combination of strong fundamentals and a favorable technical formation suggests a future upward movement for the stock.
Vericel: A GARP Investment with Strong Fundamentals and Clear Catalysts
Vericel Corporation is highlighted as a "Growth At a Reasonable Price" (GARP) investment due to its strong financial position, including a debt-free balance sheet and consistent revenue growth of around 15%. The company, specializing in advanced therapies for sports medicine and severe burn care, shows particular momentum with its MACI therapy. Investors are looking forward to the full-year and Q4 2025 financial results on February 26, 2026, for further insight into its profitability and future guidance.
Vericel: A GARP Investment with Strong Fundamentals and Clear Catalysts
Vericel Corporation is highlighted as a "Growth at a Reasonable Price" (GARP) investment opportunity due to its strong financial position, including a debt-free balance sheet, and consistent revenue growth. The company, which specializes in advanced therapies for sports medicine and severe burn care, has shown an average revenue increase of about 15.01% in recent years. Investors are eagerly awaiting Vericel's Q4 and full-year 2025 financial results on February 26, 2026, to assess its continued growth trajectory and future guidance.
Vericel Corp (NASDAQ:VCEL) Emerges as a Prime GARP Investment Candidate
Vericel Corp (NASDAQ:VCEL) is identified as a strong "Growth at a Reasonable Price" (GARP) investment candidate due to its substantial growth profile, including a 300% EPS increase and projected future growth. Despite seemingly high P/E ratios, its valuation is reasonable when compared to biotech industry peers. The company also exhibits strong profitability and a healthy financial standing with no debt, making it an attractive option for investors combining growth and value strategies.
Cartilage Repair-Cartilage Regeneration Market Covering Prime Factors and Competitive Outlook till 2026 || Vericel Corporation,Smith & Nephew PLC,Osiris Therapeutics Arthrex RTI Surgical
This article forecasts the Cartilage Repair-Cartilage Regeneration Market's growth drivers, competitive landscape, and key players until 2026. It highlights factors such as the rising incidence of orthopedic injuries, technological advancements, and increasing awareness of advanced treatments. The report also details market segmentation by application, treatment modality, and geography, alongside profiling major companies in the sector.
